Could a Preoperative Feeding Jejunostomy Decrease Sarcopenia for Patients With Oesogastric Adenocarcinoma ?

NCT03574116 | Unknown

• 1 other identifier: 6808
• Study Type: observational
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

The study of sarcopenia is a subject that is the subject of numerous research and publications, particularly because of its link with a poor prognosis for many cancers. In an article published by the digestive surgery team, the role of feeding jejunostomy has been demonstrated: it allowed more patients to reach the 2nd stage of surgery and a better tolerance of chemotherapy. Investigators wanted to study retrospectively the impact of feeding jejunostomy on radiological sarcopenia. Is the positive effect of jejunostomy in gastric cancers associated with a decrease in sarcopenia?

Conditions

Sarcopenia

Keywords

Sarcopenia; jejunostomy; oesogastric adenocarcinoma; scanography

Outcome Measures

Primary Outcomes (1)

• Evaluate muscle status by CT evaluation of sarcopenia in patients

  Evaluate the impact of feeding jejunostomy in patients with gastric cancer

  24 hour after the realization of the MRI

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Subject with Stage IB Gastric Cancer and having benefited from the placement or not of a feeding jejunostomy and a control CT performed at the HUS, after the end of the courses of chemotherapy and / or before the surger

You may qualify if:

• Age 18-80 years
• Sex: H or F
• Subject giving their consent for their participation
• Gastric cancers
• stage\> IB
• whether or not a feeding jejunostomy
• CT scan performed at the HUS, after the end of the courses of chemotherapy and / or before the surgery.

You may not qualify if:

• antecedent level L3 surgery,
• psoas hematoma
• No CT performed at HUS at the end of chemotherapy and / or before surgery
• Impossibility of giving the subject informed information
• Subject under the protection of justice
• Subject under guardianship or curatorship

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Service Imagerie 1

Strasbourg, 67098, France

RECRUITING

MeSH Terms

Conditions

Sarcopenia

Condition Hierarchy (Ancestors)

Muscular Atrophy; Neuromuscular Manifestations; Neurologic Manifestations; Nervous System Diseases; Atrophy; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms; Signs and Symptoms

Central Study Contacts

Francis VEILLON, MD, PhD

CONTACT

33 3 88 12 78 65; Francis.veillon@chru-strasbourg.fr

Aïna VENKATASAMY, MD

CONTACT

33 3 88 12 78 65; aina.venkatasamy@chru-strasbourg.fr

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 31, 2018
• First Posted: June 29, 2018
• Study Start: May 31, 2018
• Primary Completion: May 1, 2019
• Study Completion: May 1, 2019
• Last Updated: July 6, 2018

Record last verified: 2018-05

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)